Abstract
ATP is an important neurotransmitter being released with noradrenaline (NA) and neuropeptide Y (NPY) from perivascular sympathetic nerves; it acts at postjunctional P2X receptors to evoke vascular smooth muscle contraction, often synergising with the effects of NA acting at α-adrenoceptors. There is growing evidence for ATP as a neurotransmitter in perivascular non-adrenergic non-cholinergic nerves. In addition, ATP can act as a facilitatory and inhibitory neuromodulator via prejunctional P2 receptors. ATP is rapidly broken down, by ectonucleotidases, to adenosine which can also regulate the release of neurotransmitters via inhibitory prejunctional A1 adenosine receptors. The relative contributions of ATP and NA as functional cotransmitters varies with species, age, type and size of blood vessel, frequency and duration of stimulation, the tone/pressure of the blood vessel, and in disease. Blood vessel tone/pressure itself can be influenced by the vasocontractile and vasorelaxant actions of purines at different subtypes of P1 and P2 receptors, following release from the endothelium, smooth muscle, erythrocytes and platelets, as well as from perivascular nerves. This review focuses on the role of ATP as a cotransmitter in perivascular nerves in physiological and pathophysiological conditions; neuromodulator roles of purines are also discussed.
Keywords: Adenosine 5'-triphosphate (ATP), neurotransmission, noradrenaline, perivascular nerves, P2 receptors, purines, sensory nerves, sympathetic nerves
Current Vascular Pharmacology
Title: Purines as Neurotransmitters and Neuromodulators in Blood Vessels
Volume: 7 Issue: 1
Author(s): Vera Ralevic
Affiliation:
Keywords: Adenosine 5'-triphosphate (ATP), neurotransmission, noradrenaline, perivascular nerves, P2 receptors, purines, sensory nerves, sympathetic nerves
Abstract: ATP is an important neurotransmitter being released with noradrenaline (NA) and neuropeptide Y (NPY) from perivascular sympathetic nerves; it acts at postjunctional P2X receptors to evoke vascular smooth muscle contraction, often synergising with the effects of NA acting at α-adrenoceptors. There is growing evidence for ATP as a neurotransmitter in perivascular non-adrenergic non-cholinergic nerves. In addition, ATP can act as a facilitatory and inhibitory neuromodulator via prejunctional P2 receptors. ATP is rapidly broken down, by ectonucleotidases, to adenosine which can also regulate the release of neurotransmitters via inhibitory prejunctional A1 adenosine receptors. The relative contributions of ATP and NA as functional cotransmitters varies with species, age, type and size of blood vessel, frequency and duration of stimulation, the tone/pressure of the blood vessel, and in disease. Blood vessel tone/pressure itself can be influenced by the vasocontractile and vasorelaxant actions of purines at different subtypes of P1 and P2 receptors, following release from the endothelium, smooth muscle, erythrocytes and platelets, as well as from perivascular nerves. This review focuses on the role of ATP as a cotransmitter in perivascular nerves in physiological and pathophysiological conditions; neuromodulator roles of purines are also discussed.
Export Options
About this article
Cite this article as:
Ralevic Vera, Purines as Neurotransmitters and Neuromodulators in Blood Vessels, Current Vascular Pharmacology 2009; 7 (1) . https://dx.doi.org/10.2174/157016109787354123
DOI https://dx.doi.org/10.2174/157016109787354123 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obesity-Driven Inflammation and Colorectal Cancer
Current Medicinal Chemistry Multimodality Imaging in Acute Ischemic Stroke
Current Medical Imaging The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Strategies for Diabetes Prevention Before and After Pregnancy in Women with GDM
Current Diabetes Reviews A Review of Dietary Influences on Cardiovascular Health: Part 2: Dietary Patterns
Cardiovascular & Hematological Disorders-Drug Targets Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design Patent Selections
Recent Patents on Biotechnology Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics Meet the Editorial Board Member
Current Drug Targets MicroRNAs in Platelet Biogenesis and Function: Implications in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology Zinc and Cell Signaling During Inflammation: Implications in Atherosclerosis
Current Nutrition & Food Science Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis
Current Vascular Pharmacology Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Cytochrome P450 in Neurological Disease
Current Drug Metabolism Neutrophil Derived Microvesicles: Emerging Role of a Key Mediator to the Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Potential Usefulness of Clopidogrel Pharmacogenetics in Ce rebral Endovascular Procedures and Carotid Artery Stenting
Current Clinical Pharmacology